Arcadia Biosciences, Inc. (RKDA): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Arcadia Biosciences, Inc. (RKDA) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K 0001469443 false 0001469443 2026-07-01 2026-07-01 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 01,

Original reporting
Published Jul 2, 2026, 8:21 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 2, 2026, 8:24 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$RKDA
Neutral
medium confidence
Mentioned
$RKDA
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$RKDANeutralLow
01

Why it matters

Board/Compensation Committee approved a discretionary cash bonus for Schaefer for 2025 on July 1, 2026, and the 8-K updates the 2025 Summary Compensation Table accordingly.

02

Market read

This is a governance/compensation update rather than a new business milestone; it mainly affects executive compensation accounting disclosures.

03

What to watch

The 8-K also references a terminated proposed business combination (Roosevelt Resources, LP) as a reason no plan bonuses were paid for 2025; however, the termination itself is not newly disclosed here.

Relevance 6/10Novelty 4/10Timing: after-hours/filing today (8-K filed July 2, 2026)

Background

The company previously filed a 10-K/A footnote stating the 2025 bonus amount for CEO Thomas J. Schaefer was not determinable at the time of filing, with an 8-K to follow once determined.

Company-level read

Ticker impact

$RKDANeutralMedium confidence
Context

Arcadia Biosciences disclosed a discretionary 2025 cash bonus for CEO/Interim CFO Thomas J. Schaefer via Item 5.02 of an 8-K.

Expected impact

Limited near-term impact; any reaction is likely small and sentiment-driven rather than fundamental.

Evidence & confidence

This is an SEC 8-K compensation disclosure tied to a previously noted determinability footnote in the 10-K/A, not an operational or financial guidance change.

Market effects

Minimal; executive compensation mechanics typically do not reset sector expectations.

Minimal; company-specific governance/compensation disclosure.

Minimal; no cross-border deal, regulation, or product event disclosed.

Counterpoint

Traders may overreact to executive compensation headlines, but the disclosure is largely administrative—confirming a bonus amount that was previously flagged as not determinable.

Key entities

  • Arcadia Biosciences, Inc.

    Nasdaq-listed biotech company filing an 8-K to disclose discretionary executive bonus compensation and related director/shareholder meeting timing.

  • Thomas J. Schaefer

    CEO and Interim CFO; received a discretionary cash bonus for 2025, with updated compensation table totals.

  • Mark Kawakami

    Former CFO; resigned effective September 12, 2025; options expired/terminated per the filing.

Related articles

$RKDAMed

Arcadia Biosciences (RKDA) Announces Third Quarter 2026 Financial Results and Business Highlights

Arcadia Biosciences, Inc. (RKDA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Arcadia Biosciences (RKDA) Announces Third Quarter 2026 Financial Results and Business Highlights -- Zola ® Q3 revenues increase 24% year-over-year, largest quarterly sales ever -- -- New 1L espresso formulation ships this month, slim cans to launch in early 2027 --

$RKDAMed

Arcadia Biosciences (RKDA) Announces Second Quarter and First Half 2026 Financial Results and Business Highlights

Arcadia Biosciences, Inc. (RKDA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Arcadia Biosciences (RKDA) Announces Second Quarter and First Half 2026 Financial Results and Business Highlights – Net cash used in operating activities only $319K in the second quarter – – Arcadia closes $4 million private placement; ends second quarter with $4.2 m

$RKDAMedAI 9/10

Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Arcadia Biosciences (Nasdaq: RKDA) said it closed a $4 million private placement under Nasdaq rules, selling 3,883,496 shares of common stock (or pre-funded warrants) plus Series A-1 and A-2 preferred investment options to buy up to 3,883,496 shares each at $1.03/share. Gross proceeds were about $4 million. H.C. Wainwright & Co. was placement agent; proceeds will fund working capital and general corporate purposes.

$ANTHighAI 9/10

Key facts: Anthropic Reports $33.2B Revenue, Raises $10B; Cash Could Exceed $230B

Anthropic (ANT) reported $33.2B revenue for nine months, up 12x YoY, with an $81B annualized run rate but a $1.3B operating loss. It raised $10B from Alphabet and completed a $26B private placement. Analysts estimate cash could exceed $230B post-IPO. Risks include capital commitments and data-center plans. Analysts' ratings vary: Outperform, Neutral, and a $92 fair value estimate.

$ZBRAHigh

Zebra Technologies Sees 2027 Growth as Delivery Refreshes Offset Memory Cost Pressures

Zebra Technologies (ZBRA) raised prices to offset higher costs, with no broad customer project deferrals. AI applications and productivity improvements are expected to drive growth. The company anticipates $1B in free cash flow this year, with $400M remaining under its repurchase authorization. Investor sentiment has improved due to secured memory supply and interest in AI and automation.